IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults

Trial Profile

IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Etravirine (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; Atazanavir; Darunavir; Lopinavir/ritonavir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2016 Results from patients treated with Atazanavir (n=18) published in the Pediatric Infectious Disease Journal
    • 16 May 2016 Results of pharmacokinetics of rilpivirine with and without darunavir/ritonavir (n=28) published in the Pediatric Infectious Disease Journal
    • 16 May 2014 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top